Estimation of the warfarin dose with clinical and pharmacogenetic data.

BACKGROUND Genetic variability among patients plays an important role in determining the dose of warfarin that should be used when oral anticoagulation is initiated, but practical methods of using genetic information have not been evaluated in a diverse and large population. We developed and used an algorithm for estimating the appropriate warfarin dose that is based on both clinical and genetic data from a broad population base. METHODS Clinical and genetic data from 4043 patients were used to create a dose algorithm that was based on clinical variables only and an algorithm in which genetic information was added to the clinical variables. In a validation cohort of 1009 subjects, we evaluated the potential clinical value of each algorithm by calculating the percentage of patients whose predicted dose of warfarin was within 20% of the actual stable therapeutic dose; we also evaluated other clinically relevant indicators. RESULTS In the validation cohort, the pharmacogenetic algorithm accurately identified larger proportions of patients who required 21 mg of warfarin or less per week and of those who required 49 mg or more per week to achieve the target international normalized ratio than did the clinical algorithm (49.4% vs. 33.3%, P<0.001, among patients requiring < or = 21 mg per week; and 24.8% vs. 7.2%, P<0.001, among those requiring > or = 49 mg per week). CONCLUSIONS The use of a pharmacogenetic algorithm for estimating the appropriate initial dose of warfarin produces recommendations that are significantly closer to the required stable therapeutic dose than those derived from a clinical algorithm or a fixed-dose approach. The greatest benefits were observed in the 46.2% of the population that required 21 mg or less of warfarin per week or 49 mg or more per week for therapeutic anticoagulation.

[1]  D. Sackett,et al.  The number needed to treat: a clinically useful measure of treatment effect , 1995, BMJ.

[2]  Posting Presentations at Medical Meetings on the Internet , 1999 .

[3]  Andreas Fregin,et al.  Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 , 2004, Nature.

[4]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[5]  M. Margaglione,et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.

[6]  Mark Crowther,et al.  Systematic overview of warfarin and its drug and food interactions. , 2005, Archives of internal medicine.

[7]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.

[8]  S. Hunt,et al.  Common VKORC1 and GGCX polymorphisms associated with warfarin dose , 2005, The Pharmacogenomics Journal.

[9]  M. Shearer,et al.  Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1 , 2004, Thrombosis and Haemostasis.

[10]  P. Deloukas,et al.  Association of warfarin dose with genes involved in its action and metabolism , 2006, Human Genetics.

[11]  H. Halkin,et al.  Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin , 2006, Thrombosis and Haemostasis.

[12]  Ling-Zhi Wang,et al.  A warfarin‐dosing model in Asians that uses single‐nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9 , 2006, Clinical pharmacology and therapeutics.

[13]  M. Ritchie,et al.  Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans , 2006, Pharmacogenetics and genomics.

[14]  V. Dolžan,et al.  The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement , 2006, Thrombosis and Haemostasis.

[15]  Julie A. Johnson,et al.  Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements , 2006, Clinical pharmacology and therapeutics.

[16]  F. Kamali,et al.  APOE genotype makes a small contribution to warfarin dose requirements. , 2006, Pharmacogenetics and genomics.

[17]  B. Horne,et al.  Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.

[18]  Ingrid Glurich,et al.  Evaluation of Genetic Factors for Warfarin Dose Prediction , 2007, Clinical Medicine & Research.

[19]  D. Wysowski,et al.  Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. , 2007, Archives of internal medicine.

[20]  C. Richards,et al.  Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults , 2007, Annals of Internal Medicine.

[21]  Alan H B Wu,et al.  Use of genetic and nongenetic factors in warfarin dosing algorithms. , 2007, Pharmacogenomics.

[22]  Larisa H Cavallari,et al.  Factors influencing warfarin dose requirements in African-Americans. , 2007, Pharmacogenomics.

[23]  H. Halkin,et al.  A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. , 2007, Blood.

[24]  Y. Kokubo,et al.  Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. , 2007, Thrombosis research.

[25]  C. Thorn,et al.  Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and Caucasians , 2007, Clinical pharmacology and therapeutics.

[26]  Deepak Voora,et al.  Genetic-based dosing in orthopedic patients beginning warfarin therapy. , 2007, Blood.

[27]  E. Hylek,et al.  Genetic Testing for Warfarin Dosing? Not Yet Ready for Prime Time , 2008, Pharmacotherapy.

[28]  E. Nabel,et al.  Pharmacogenomics--ready for prime time? , 2008, The New England journal of medicine.

[29]  R. Lutter,et al.  Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin. , 2008, Personalized medicine.

[30]  Y. Caraco,et al.  CYP2C9 Genotype‐guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study , 2008, Clinical pharmacology and therapeutics.

[31]  R. Desnick,et al.  Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. , 2008, American journal of human genetics.

[32]  C. Thorn,et al.  Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans , 2008, The Pharmacogenomics Journal.

[33]  Y. Turpaz,et al.  CYP4F2 genetic variant alters required warfarin dose. , 2008, Blood.

[34]  Y. Caraco,et al.  CYP 2 C 9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation : A Prospective Randomized Controlled Study , 2011 .